EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Granzyme A as biomarker for diagnosis in tuberculous pleural effusion

Fuxiang Li, Chuanzhi Zhu, Yue Zhang, Fanhui Kong, Ximeng Zhang, Liping Pan, Hongyan Jia, Liang Fu, Yunlong Hu, Guofang Deng, Qianting Yang, Xinchun Chen und 1 weitere

JCI Insight · 2024

DOI: 10.1172/jci.insight.185307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, 2024. Verfasst von Fuxiang Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Department of Pathogen Biology, Shenzhen University Medical School, Shenz…. Hauptthemen laut MEDLINE: Granzymes, Biomarkers, Pleural Effusion. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Project of Shenzhen, Shenzhen Medical Research Funding, Provincial Natural Science Foundation of Guangdong.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Current diagnostic tools for tuberculous pleural effusion (TPE) are often inadequate, making accurate diagnosis challenging. Effective identification of TPE is critical for ensuring proper treatment and preventing tuberculosis relapse. This study explored the potential of granzyme A (GZMA) as a biomarker for TPE. METHODS Patients with TPE, malignant pleural effusion (MPE), and parapneumonic pleural effusion (PPE) were recruited into discovery and validation cohorts. The discovery cohort consisted of 200 patients with TPE and 100 patients with MPE, while the validation cohort included 167 patients with TPE, 84 patients with MPE, and 69 patients with PPE. RESULTS In the discovery cohort, GZMA levels were significantly elevated in TPE compared with MPE, demonstrating 90% sensitivity and 91% specificity at a cutoff of 102.29 ng/mL for effectively distinguishing between the two conditions. In the validation cohort, GZMA maintained high diagnostic performance, distinguishing TPE from MPE with 87% sensitivity and 87% specificity and from PPE with 87% sensitivity and 84% specificity. Incorporating GZMA, lactate dehydrogenase (LDH), and adenosine deaminase (ADA) into a random forest model further improved diagnostic accuracy. In the discovery cohort, this model achieved 92% sensitivity and 100% specificity, and in the validation cohort, it distinguished TPE from MPE with 87% sensitivity and 94% specificity and from PPE with 87% sensitivity and 91% specificity. CONCLUSION Overall, GZMA is a promising biomarker for diagnosing TPE, with improved accuracy when combined with LDH and ADA, providing a robust tool for timely identification and effective management of patients with TPE. FUNDING The study was supported by Science and Technology Project of Shenzhen (KCXFZ20211020163545004, KQTD20210811090219022, JCYJ20220818095610021, JSGG20220822095200001, JCYJ20210324094614038), Shenzhen Medical Research Funding (B2302035, A2302004), Provincial Natural Science Foundation of Guangdong (2022A1515220034), and Shenzhen Third People’s Hospital Research Foundation (G2022155).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GranzymesBiomarkersPleural EffusionHumansFemaleMaleMiddle AgedAgedTuberculosis, PleuralSensitivity and SpecificityAdultAdenosine DeaminasePleural Effusion, MalignantL-Lactate Dehydrogenase

Stichwörter der Autor:innen

Infectious diseaseTuberculosis

Substanzen

GranzymesBiomarkersGZMA protein, humanAdenosine DeaminaseL-Lactate Dehydrogenase

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Department of Pathogen Biology, Shenzhen University Medical School, Shenzhen, China.
  • Department of Biochemistry, Center for Molecular Biomedicine, Friedrich Schiller University Jena, Jena, Germany.
  • Laboratory of Molecular Biology, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing,…
  • School of Pharmaceutical Sciences, Shenzhen University Medical School, Shenzhen, China.
  • Department of Microbiology, Wu Lien-Teh Institute, Harbin Medical University, Harbin, China.
  • Guangdong Key Lab for Diagnosis & Treatment of Emerging Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, China.

Förderung

  • Science and Technology Project of Shenzhen
  • Shenzhen Medical Research Funding
  • Provincial Natural Science Foundation of Guangdong
  • Shenzhen Third People’s Hospital Research Foundation

Zitieren

APA

Li, F., Zhu, C., Zhang, Y., Kong, F., Zhang, X., Pan, L., Jia, H., Fu, L., Hu, Y., Deng, G., Yang, Q., Chen, X., & Cai, Y. (2024). Granzyme A as biomarker for diagnosis in tuberculous pleural effusion. JCI Insight. https://doi.org/10.1172/jci.insight.185307

Vancouver

Li F, Zhu C, Zhang Y, Kong F, Zhang X, Pan L, et al. Granzyme A as biomarker for diagnosis in tuberculous pleural effusion. JCI Insight. 2024. doi:10.1172/jci.insight.185307

BibTeX
@article{Li2024,
  author = {Li, Fuxiang and Zhu, Chuanzhi and Zhang, Yue and Kong, Fanhui and Zhang, Ximeng and Pan, Liping and Jia, Hongyan and Fu, Liang and Hu, Yunlong and Deng, Guofang and Yang, Qianting and Chen, Xinchun and Cai, Yi},
  title = {Granzyme A as biomarker for diagnosis in tuberculous pleural effusion},
  journal = {JCI Insight},
  year = {2024},
  doi = {10.1172/jci.insight.185307}
}
Kostenlos starten →